At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
Ezogabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis
In Brief
A Phase 2 clinical trial evaluating Ezogabine and Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 65 participants across 12 sites.
Detailed Summary
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionJan 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedMay 21, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 1, 2018
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.1 years ago
Interventions
Ezogabinedrug
Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
Placebodrug
Matched placebo